Search the Newsreel

Candel Therapeutics (NASDAQ:CADL) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen has downgraded Candel Therapeutics (NASDAQ:CADL) to a "Sell" rating, despite a broader "Moderate Buy" consensus among analysts with an average price target of $19.29. The downgrade follows Candel's quarterly loss of $0.52 per share, significantly missing analyst estimates. While management targets …

Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell

Wall Street Zen has downgraded Spyre Therapeutics (NASDAQ:SYRE) from "hold" to "sell," despite a broader "Moderate Buy" consensus from other analysts with an average target price of $111.69. The company's shares opened at $103.63, near a 52-week high, and it reported a quarterly loss …

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

Should I buy Scribe Therapeutics Inc. (SCTX)

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug

Madrigal Pharmaceuticals (MDGL) is attracting retail investor attention due to newly acquired U.S. patents for its lead liver disease drug, Rezdiffra, and ongoing speculation about a potential acquisition, possibly by Eli Lilly. Rezdiffra is Madrigal's sole marketed product, and the company is actively expanding …

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX

Walleye Capital LLC has acquired 245,587 new shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the second quarter, valuing the stake at approximately $2.19 million and representing 0.40% of the company. Despite beating Q2 earnings estimates, Kyverna Therapeutics, a clinical-stage biotech company focused on T-cell …

Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen

Keros Therapeutics (NASDAQ:KROS) has been downgraded to a "strong sell" rating by Wall Street Zen. This comes as the company's shares opened near their 52-week low and reported a larger-than-expected quarterly loss of $1.45 per share. Despite the downgrade, the broader analyst consensus for …

Understanding the Setup: (ABEO) and Scalable Risk

This article analyzes Abeona Therapeutics Inc. (NASDAQ: ABEO), highlighting conflicting sentiment and a mid-channel oscillation pattern. It presents an exceptional 55.0:1 risk-reward setup targeting a 19.3% gain against 0.4% risk. The article outlines three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe …

Financial Institutions, Inc. remains a Buy with improved profitability and strong valuation.

Financial Institutions, Inc. (FISI) has maintained a Buy rating due to its improved profitability and strengthened capital ratios. The company's net interest margin increased to 3.70% in Q2 2026, driven by reduced funding costs and higher-yielding loan replacements. FISI also presents an attractive valuation …

Financial Institutions: Still A Cautious Buy With Improved Outlook

Financial Institutions Stock: Still A Cautious Buy With Improved Outlook (NASDAQ:FISI)

Price-Driven Insight from (ZVRA) for Rule-Based Strategy

This article provides a price-driven analysis for Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and an exceptional risk-reward short …

Arcutis (ARQT) Q2 2026 Earnings Call Transcript

₹524: That's What Analysts Think Awfis Space Solutions Limited (NSE:AWFIS) Is Worth After Its Latest Results

Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress

Nektar Therapeutics' stock fell 4% following its Q2 2026 earnings report, despite progress in its autoimmune pipeline, notably rezpegaldesleukin. The market reacted negatively to the company's substantial cash burn, with a quarterly net loss exceeding US$40 million and trailing 12-month losses widening. While the …

Will Rising Revenue But Mounting Losses and Steady Payouts Change Brookfield Wealth Solutions' (BNT) Narrative

Brookfield Wealth Solutions Ltd. (NYSE:BNT) Short Interest Update

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints

How Rapport Therapeutics Inc. (RAPP) Affects Rotational Strategy Timing

This article analyzes Rapport Therapeutics Inc. (RAPP) using AI models to determine its effect on rotational strategy timing. Key findings suggest a strong sentiment supporting an overweight bias, with resistance being tested. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, …

Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5

Maxim Group has reiterated its Buy rating for Aprea Therapeutics (APRE.US) and maintained its price target of $5. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) reported a Q2 loss of $0.31 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. However, the company missed revenue estimates, posting $5.15 million against an expected $5.43 million. Despite beating EPS estimates two out …

PDF Solutions (PDFS) Posts Stronger Results, Is The Upside Already Priced In?

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC

Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker

An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous …

Shanghai Fudan Zhangjiang Bio Pharmaceutical Ltd (SEHK:1349) Stock Profit Rebound Raises Durability Questions

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement

Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals (NASDAQ: ETON) saw its shares rise significantly in pre-market trading after reporting stronger-than-expected second-quarter financial results and providing an optimistic revenue guidance for FY26. The company exceeded analyst consensus estimates for both earnings per share and sales. The article also lists other …

TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …

Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026

Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …

Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?

BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …

ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that invest in Regeneron Pharmaceuticals, Inc. (RGO) stocks. The list, sorted by market value, details each fund's symbol, market value, weight of RGO stock, issuer, management style, focus, expense ratio, assets under management …